Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.
Journal: The Lancet. Infectious diseases
Published: January 16, 2026
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.
Journal: Journal of cachexia, sarcopenia and muscle
Published: May 28, 2024
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Journal: The New England journal of medicine
Published: March 23, 2022
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Journal: The New England journal of medicine
Published: May 27, 2021
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Journal: The Pediatric infectious disease journal
Published: August 28, 2020
Corrigendum to 'Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults'. [Vaccine 36 (2018) 6325-6333].
Journal: Vaccine
Published: February 17, 2020
Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: July 25, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026